Pre-Cure

Company Overview

Snapshot

Founded in May 2023 by Dan Simhon, Pre-Cure operates with 1–10 employees. The company has secured one funding round to date and is currently in the Pre-Seed stage. In October 2023, Pre-Cure was highlighted for its cutting-edge customized microfluidic tumor-on-a-chip technology, designed to accelerate cancer treatment.

Business overview

Pre-Cure is a Health Tech & Life Sciences company focused on transforming cancer treatment selection. The company develops a multifunctional tumor-on-a-chip platform and 3D cell culture models, aiming to create a "patient-on-a-chip" system that reflects the entire clinical journey. This technology provides accurate individual therapy predictions, serving the pharmaceuticals sector within the broader healthcare and life sciences market.

Strategic signal

In October 2023, Pre-Cure gained recognition for its customized microfluidic tumor-on-a-chip technology, which is designed to accelerate cancer treatment. This development signals the company's commitment to advancing personalized medicine in oncology and indicates potential for significant impact on drug discovery and patient-specific therapeutic approaches.

Company Intelligence Q&A

What is Pre-Cure's core technology?

Pre-Cure's core technology is a multifunctional tumor-on-a-chip platform and 3D cell culture models, designed to provide accurate individual therapy predictions for cancer treatment.

When was Pre-Cure founded?

Pre-Cure was founded in May 2023.

What was a significant development for Pre-Cure in October 2023?

In October 2023, Pre-Cure was recognized for its cutting-edge customized microfluidic tumor-on-a-chip technology, which aims to accelerate cancer treatment.

Who is a founder of Pre-Cure?

Dan Simhon is a founder of Pre-Cure.

What is Pre-Cure's primary sector?

Pre-Cure's primary sector is Health Tech & Life Sciences, specifically focusing on Drugs Discovery & Development within Pharma & Medical Biotechnology.